NuVox Pharma may soon have the answer to fighting complications from sickle cell disease after getting approval from the FDA to test its new drug, NVX-508.

Kelly Presnell / Arizona Daily Star 2014

Tucson-based drug startup NuvOx Pharma LLC has exclusively licensed one of its drug candidates to a Chinese company, for development and sales in China for treating hemorrhagic shock and surgery-related blood loss.

Terms of the deal with Jiangsu Nhwa Pharmaceutical Co. Ltd. were not disclosed.

Founded by University of Arizona radiologist Dr. Evan Unger, NuvOx is developing oxygen-based therapeutics for cancer and other ailments.

The licensed drug, NVX-408, is injected intravenously and releases oxygen to hypoxic, or oxygen-starved, tissue. Pre-clinical studies show that it can improve survival during severe blood loss. NuvOx said.

Other NuvOx drugs are in clinical trials for hypoxic solid tumors, acute ischemic stroke and sickle cell disease.